News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ReVance Therapeutics, Inc. (RVNC) Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Over-Allotment Option


2/12/2014 9:12:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its initial public offering of 6,900,000 shares of common stock at a public offering price of $16.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock at the same price to cover over-allotments. Gross proceeds from the sale of the shares is approximately $110 million. The net proceeds from the sale of the shares, after deducting the underwriters' discount and other estimated offering expenses will be approximately $98.7 million.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES